Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results